The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes (SFB636D6)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00926900|
Recruitment Status : Unknown
Verified November 2011 by Central Institute of Mental Health, Mannheim.
Recruitment status was: Recruiting
First Posted : June 24, 2009
Last Update Posted : November 28, 2011
The aim of this project is to explore whether the extinction of cue-reactivity following a cue-exposure based intervention in volunteers with an alcohol dependence is facilitated by drugs that increase NMDA-receptor function.
It is hypothesised that targeted treatment with D-Cycloserine prior to each extinction training session enhances the effects on cue-reactivity.
Further, a significant correlation between the reduction of cue-reactivity and both reduced craving and relapse probability is expected.
|Condition or disease||Intervention/treatment||Phase|
|Alcohol Drinking||Drug: D-cycloserine Drug: Placebo||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Primary Purpose:||Basic Science|
|Official Title:||The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes|
|Study Start Date :||March 2009|
|Estimated Primary Completion Date :||April 2012|
|Active Comparator: D-cycloserine||
50 mg at approximately 1.5 hours prior to cue-exposure training sessions
|Placebo Comparator: Placebo||
- reduction in cue-reactivity to alcohol-associated stimuli assessed by functional magnetic resonance imaging [ Time Frame: following completion of cue-exposure therapy ]
- time to first severe relapse to alcohol consumption [ Time Frame: at 3 and 6 months after treatment completion ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00926900
|Contact: Falk Kiefer, Professor||+49 621 1703 email@example.com|
|Central Institute of Mental Health||Recruiting|
|Mannheim, Germany, 68159|
|Contact: Falk Kiefer, Professor +49 621 1703 3522 firstname.lastname@example.org|
|Principal Investigator: Falk Kiefer, Professor|
|Principal Investigator:||Falk Kiefer, Professor||Central Institute of Mental Health, Department of Addictive Behavior and Addiction Medicine|